Hercules Capital, Inc. (HTGC) 2019 10-K Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for Hercules Capital, Inc. for the fiscal year ended December 31, 2019. Hercules is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC) and a Regulated Investment Company (RIC). The company focuses on providing senior secured loans, primarily structured debt with warrants, to high-growth, venture capital-backed companies in technology, life sciences, and sustainable/renewable technology sectors.
Key Financial Metrics
| Metric | 2019 Value | 2018 Value |
|---|---|---|
| Total Assets | $2.46 billion | $1.95 billion |
| Total Investments (at value) | $2.31 billion | $1.88 billion |
| Total Net Assets | $1.13 billion | $0.96 billion |
| Net Asset Value (NAV) per Share | $10.55 | $9.90 |
| Total Investment Income | $267.9 million | $207.8 million |
| Net Investment Income | $143.3 million | $108.7 million |
| Net Realized Gain (Loss) | $16.5 million | ($11.1 million) |
| Net Unrealized Appreciation (Depreciation) | $13.8 million | ($21.1 million) |
| Net Increase in Net Assets from Operations | $173.6 million | $76.5 million |
| Weighted Average Cost of Debt | 5.2% | 5.6% |
| Effective Yield on Debt Investments | 13.4% | 13.7% |
| Total Debt Outstanding | ~$1.30 billion | ~$0.99 billion |
| Asset Coverage Ratio (excluding SBA) | 198.0% | N/A |
| Unfunded Commitments | $133.7 million | $139.0 million |
Material Changes vs. Prior Period
- Portfolio Growth: Total investment portfolio value increased by approximately $434 million (23%) from 2018 to 2019, driven by new fundings of $1.03 billion and restructures.
- Income Growth: Net investment income rose 32% to $143.3 million, primarily due to portfolio growth and income acceleration from early repayments.
- Realized Gains: The company reported net realized gains of $16.5 million in 2019, a significant improvement from net realized losses of $11.1 million in 2018. Gains were driven by sales of public equity holdings and M&A transactions.
- Unrealized Appreciation: The portfolio recorded $13.8 million in net unrealized appreciation in 2019, reversing the $21.1 million depreciation seen in 2018.
- Expense Increase: Total operating expenses increased to $124.6 million from $99.0 million. This was driven by higher interest expense due to new debt issuances (2028 Asset-Backed Notes, July 2024 Notes) and increased general and administrative expenses related to legal fees and SEC cooperation.
- Debt Structure: The company issued $250 million in 2028 Asset-Backed Notes and $105 million in July 2024 Notes, while fully redeeming the remaining $83.5 million of 2024 Notes.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted a strong year with significant portfolio growth and improved credit quality. The weighted average investment grading of the debt portfolio improved slightly to 2.15 (on a scale of 1-5) from 2.18 in 2018. The company continues to target a total annualized return of 12% to 25% on debt investments.
Outlook: The company maintains a variable distribution policy targeting 90-100% of taxable income. On February 12, 2020, the Board declared a quarterly distribution of $0.32 per share and a supplemental distribution of $0.08 per share.
Risks and Contingencies:
- Concentration Risk: Approximately 86.7% of the portfolio is concentrated in five industries, with "Drug Discovery & Development" (32.2%), "Software" (25.2%), and "Internet Consumer & Business Services" (21.4%) being the largest.
- Valuation Uncertainty: Approximately 94% of total assets are Level 3 investments valued in good faith by the Board, lacking readily available market prices.
- Leverage: The company utilizes significant leverage. A decline in asset values could disproportionately impact NAV due to the fixed obligations of debt.
- Regulatory Compliance: As a BDC and RIC, the company must maintain specific asset coverage ratios (150%) and distribution requirements to avoid corporate-level taxation.
- SEC Investigation: The filing notes increased legal and administrative expenses in 2019 related to cooperation with the SEC regarding document requests received in March 2019.
Key Facts for Investor Verification
- NAV vs. Market Price: Verify the current trading price of HTGC relative to the reported NAV of $10.55 to assess the discount/premium.
- Debt Maturities: Review the maturity schedule of the $1.3 billion in debt, noting significant tranches due in 2022 (Convertible Notes, 2022 Notes) and 2024 (July 2024 Notes).
- Portfolio Concentration: Assess the risk exposure to the top six portfolio companies, which represented over 38% of net assets (BridgeBio, Oak Street Health, Paratek, EverFi, Tricida, Businessolver).
- Unfunded Commitments: Confirm the company's liquidity position ($235.5 million available) against $133.7 million in unfunded commitments.
- SEC Cooperation: Monitor updates regarding the SEC document requests mentioned in the risk factors and expense discussions.